Description and optimization of a multiplex bead-based flow cytometry method (MBFCM) to characterize extracellular vesicles in serum samples from patients with hematological malignancies.

Autor: Li L; Working-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany. Lin.Li@med.uni-muenchen.de., Görgens A; Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden., Mussack V; Department of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany., Pepeldjiyska E; Working-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany., Hartz AS; Working-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany., Rank A; Department of Hematology and Oncology, University Hospital of Augsburg, Augsburg, Germany., Schmohl J; Department of Hematology and Oncology, Hospital of Stuttgart, Stuttgart, Germany., Krämer D; Department of Heamatology, Oncology and Palliative Care, Ameos Klinikum Mitte, Bremerhaven, Germany., Andaloussi SE; Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden., Pfaffl MW; Department of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany., Schmetzer H; Working-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany. Helga.Schmetzer@med.uni-muenchen.de.
Jazyk: angličtina
Zdroj: Cancer gene therapy [Cancer Gene Ther] 2022 Nov; Vol. 29 (11), pp. 1600-1615. Date of Electronic Publication: 2022 Apr 27.
DOI: 10.1038/s41417-022-00466-1
Abstrakt: Extracellular Vesicles (EVs) are membranous vesicles produced by all cells under physiological and pathological conditions. In hematological malignancies, tumor-derived EVs might reprogram the bone marrow environment, suppress antileukemic immunity, mediate drug resistance and interfere with immunotherapies. EVs collected from the serum of leukemic samples might correlate with disease stage, drug-/immunological resistance, or might correlate with antileukemic immunity/immune response. Special EV surface protein patterns in serum have the potential as noninvasive biomarker candidates to distinguish several disease-related patterns ex vivo or in vivo. EVs were isolated from the serum of acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL) patients, and healthy volunteers. EVs were characterized by transmission electron microscopy and fluorescence nanoparticle tracking analysis, and EV surface protein profiles were analyzed by multiplex bead-based flow cytometry to identify tumor- or immune system-related EVs of AML, ALL, CLL, and healthy samples. Aiming to provide proof-of-concept evidence and methodology for the potential role of serum-derived EVs as biomarkers in leukemic versus healthy samples in this study, we hope to pave the way for future detection of promising biomarkers for imminent disease progression and the identification of potential targets to be used in a therapeutic strategy.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: